A number of other research firms also recently weighed in on HTGM. Zacks Investment Research raised shares of HTG Molecular Diagnostics from a sell rating to a hold rating in a research note on Wednesday, July 13th. Rodman & Renshaw began coverage on shares of HTG Molecular Diagnostics in a research note on Monday, August 22nd. They issued a buy rating and a $5.00 price target on the stock. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. HTG Molecular Diagnostics presently has a consensus rating of Buy and a consensus price target of $5.25.
HTG Molecular Diagnostics (NASDAQ:HTGM) opened at 3.00 on Thursday. The firm’s market cap is $21.15 million. The company has a 50 day moving average price of $2.51 and a 200 day moving average price of $2.65. HTG Molecular Diagnostics has a 1-year low of $2.03 and a 1-year high of $6.03.
HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.98) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.95) by $0.03. On average, equities research analysts forecast that HTG Molecular Diagnostics will post ($3.58) earnings per share for the current year.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc and related companies with MarketBeat.com's FREE daily email newsletter.